Research programme: G-protein coupled receptor agonists - Confo Therapeutics/Roche

Drug Profile

Research programme: G-protein coupled receptor agonists - Confo Therapeutics/Roche

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Confo Therapeutics
  • Developer Confo Therapeutics; Roche
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Developmental disabilities; Neurological disorders

Most Recent Events

  • 19 Dec 2017 Confo Therapeutics and Roche agree to co-develop and commercialise GPCR agonists for Neurological disorders and Developmental disabilities
  • 19 Dec 2017 Early research in Developmental disabilities in Belgium (unspecified route)
  • 19 Dec 2017 Early research in Neurological disorders in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top